Sclerotherapy Spider Vein Injections


What is sclerotherapy?

Sclerotherapy (also known as chemical ablation) is typically used to treat smaller veins and branches of large veins, such as spider veins and reticular veins. Sclerotherapy involves the injection of a sclerosant agent into problem veins, which causes a chain of biological reactions that eliminate the target veins.⁶


How do sclerotherapy vein injections work?

The injection kit and sclerosant formulation are prepared

A small needle is inserted into the target vein

Sclerosant is injected, causing the vein to respond immediately

Sclerosant causes vein irritation, dehydration, and destruction


Are sclerotherapy vein injections clinically proven?

Clinical evidence supports the use of sclerotherapy agents, including Asclera, to eliminate spider veins and reticular veins. In the EASI study, approximately 85% of individuals treated with Asclera were still satisfied with treatment six months afterwards.⁷

While other providers may offer laser therapy to treat spider veins, we choose to use sclerotherapy for its proven advantages over laser therapy, including:


(1) the ability to treat larger feeder veins and veins that lie farther underneath the surface of the skin ⁹

(2) faster resolution and less pain than laser treatment ⁸⁻⁹

(3) sclerotherapy usually only requires one or two treatment sessions for complete resolution, while laser typically requires more ⁹

In addition to treating cosmetic vein problems, it is common practice to use sclerotherapy after varicose vein treatment (ClosureFast™ thermal vein closure or VenaSeal™) to eliminate small vein branches if needed.²


Are sclerotherapy vein injections right for me?

Give us a call at (972) 646-8346 to schedule a free consultation and learn more about your personalized treatment options.


Learn More

Laser treatment or vein injection treatment for spider veins?

Relationship between Spider Veins & More Serious Vein Problems

Ultrasound-guided foam sclerotherapy vein treatment explained



​[6] Kugler, N. W., & Brown, K. R. (2017). An update on the currently available nonthermal ablative options in the management of superficial venous disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 5(3), 422–429.

[7] Bertanha, M., Camargo, P. A. B. de, Moura, R., Yoshida, W. B., Pimenta, R. E. F., Mariúba, J. V. de O., … Sobreira, M. L. (2016). Polidocanol versus glucose in the treatment of telangiectasia of the lower limbs (PG3T). Medicine, 95(39), e4812.

[8] Rabe, E., Schliephake, D., Otto, J., Breu, F. X., & Pannier, F. (2010). Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology: The Journal of Venous Disease, 25(3), 124–131.

[9] Parlar, B., Blazek, C., Cazzaniga, S., Naldi, L., Kloetgen, H. W., Borradori, L., & Buettiker, U. (2015). Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: A prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology, 29(3), 549–554.

[10] Morrison, N., Gibson, K., Vasquez, M., Weiss, R., Cher, D., Madsen, M., & Jones, A. (2017). VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 5(3), 321–330.

Our Locations

Choose your preferred location